{"denomUnitsSelected":"Participants","description":"Number of participants with hematologic toxicity during treatment period, where hematologic toxicity is defined as occurrence of any grade 3 or higher adverse events for neutropenia, leukopenia, lymphopenia, anemia, or thrombocytopenia. Adverse events are graded and categorized using CTCAE v4.0.","reportingStatus":"NOT_POSTED","timeFrame":"Up to 30 days after completion of study treatment","title":"Number of Participants With Hematologic Toxicity During Treatment Period","type":"OTHER_PRE_SPECIFIED"}